Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines

The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.

Cancer In Vitro Diagnostics Personalized Medicine

CDRH’s New Post-Market Paradigm: Why The Public Should Be Worried

Strengthening the flow of real-world evidence on medical devices is at the heart of US FDA's evolving paradigm of device oversight. An underlying promise of the new approach is that a better post-market safety net will allow the agency's device center to take more risk in the pre-market phase, accelerating product development. But while safety surveillance is an important goal, the device center's recent actions and its April-issued Medical Device Safety Action Plan signal that it wants dramatic changes in its authority to decide how best to respond to perceived post-market safety signals, carrying potentially significant negative consequences for the public health, argues attorney Bradley Merrill Thompson in this guest column.

Regulation Legal Issues FDA

Hindsight 20/20: Elekta's Kevin Brown

Hindsight 20/20 is a Q&A feature where veterans of the medtech industry share career highlights, specific achievements and hurdles they have faced. In this installment, Kevin Brown, global VP of scientific research at radiation therapy specialist Elekta, discusses the challenges of translating scientific ideas into breakthrough technologies that bring value to clinicians and patients. He also addresses his guiding principles for picking winning ideas and his journey bringing to market the world's first integrated MRI and radiotherapy system.

Hindsight 20/20 Innovation Research and Development Strategies

Mid-Year Enforcement Roundup: Focus On Opioids, As Other Areas Lag

A recent report from law firm Gibson Dunn seems to show that the Trump administration, while aggressively pursuing opioid enforcement actions, slowed down enforcement in other areas during the first half of 2018. But important case-law developments continue.

Policy & Regulation Analysis Enforcement

QUOTED. Aug. 14, 2018. Dawood Sayed.

The American Society of Pain and Neuroscience is teaming up with Ethos Laboratories to investigate the relationship of urine-measured biomarkers with pain interventions. See what ASPN President Dawood Sayed said about it here.

Quoted Personalized Medicine Commercial

Latest from PR Newswire

Click here to access further medical device and diagnostics news.
 
Advertisement


Recent Tweets from Medtech Insight


Getting The Words Right: Device Documentation And Translation in Asia

Oracle Health Sciences

Although the medical device sector has seen increasing harmonization of regulations both globally and regionally, market-entry requirements in Asia still retain a significant degree of localization, particularly as they relate to product labeling and documentation.

Download the article to learn more about the challenges and potential rewards of device documentation and translation in Asia.

The article reviews:

  • New regulatory reforms and their impact
  • The role and limitations of localizing software
  • Opportunities to translate for growth

Read Article

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

Policy & Regulation Explore this Topic

Set Alert for Policy

Device Week, Aug. 10, 2018 – Cancer Center Steps Up To Pass Combo Product

On this week’s podcast, Medtech Insight’s Catherine Longworth and Ferdous Al-Faruque talk about surgical guidance company Endomag, which recently secured a landmark approval from US FDA for its combination breast cancer product Sentimag and Magtrace.

Device Week Combination Products Cancer

India Releases ‘Essential Reference Manual’ On Devices And IVDs

The Indian government is seeking feedback on a draft guidance document that covers everything industry needs to know about the country’s regulatory requirements for medtech products.

Policy & Regulation India Medical Device

Warning Letter Roundup & Recap – Aug. 14, 2018

No device-related warning letters were released by US FDA the week of Aug. 14.
Device Warning Letters FDA

QUOTED. Aug. 13, 2018. Jonathan Phillips.

When it comes to opioids and enforcement, the US Department of Justice is largely focused on the drug side. But Gibson Dunn attorney Jonathan Phillips says that doesn’t mean device-makers should be complacent about opioid enforcement activities. See what he said here.

Quoted Enforcement

FDA Approves Birth Control Mobile App, Vaginal Ring

US FDA announced the approval of the first direct-to-consumer mobile medical app that can prevent pregnancy via fertility awareness tracking. The app, Natural Cycles, has been criticized in Europe after some users experienced unplanned pregnancies. On the same day, the agency approved the first contraceptive vaginal ring that can be reused for an entire year.

Medical Device Gynecology & Urology

UDI Database Deadline Extended Again For Certain Combo Products

Following an extension for Unique Device Identifier requirements for low-risk devices earlier this summer, US FDA has pushed back a deadline to input UDI date into its GUDID database for combination products that go through the drug center. Manufacturers, however, are still required to implement UDIs labeling by Sept. 24.

Combination Products Compliance

CMS Finalizes Spending Per Beneficiary Quality Measure Over MDMA Objections

The US Medicare agency in its final 2019 Inpatient Prospective Payment System rule plans to continue assessing patients’ outcomes under its Hospital Value-Based Program in part with a Medicare spending per beneficiary measure, despite industry warnings that doing so may sacrifice patient quality of care.

Reimbursement Regulation

New Cancer Center Played Pivotal Role In Endomag's Success

US FDA's new Oncology Center for Excellence brought in key experts to help review and approve Endomag's new Magtrace and Sentimag System combination product to help surgeons trace and remove breast tumors. The case highlights how disease-specific centers could change the way the agency reviews products, and it also spotlights the agency's recent efforts to improve combination product reviews. Check out our Q&A with FDA's Binita Asher.

Combination Products Cancer

Quality Control & Compliance Explore this Topic

Set Alert for Quality Control

Q2 Recalls Snapshot: Industry Sets Record Again With Most Quarterly Recalls Since '05

A record 360 recall events were initiated by device-makers in the second quarter of 2018, beating the previous high of 343 product recalls recorded in Q1. On a somewhat brighter note, the number of device units recalled in Q2 fell a whopping 80% from the prior quarter. Check out our Q2 recalls infographic.

Recalls Safety

MDSAP Auditors Aren't Applying A Consistent Auditing Approach, Medtech Group DITTA Claims In Letter To FDA

A letter from DITTA Chair Patrick Hope to a US FDA point person for MDSAP highlights concerns some device-makers have about the flourishing Medical Device Single Audit Program, including inconsistent auditing approaches from facility to facility, and long-delayed audit results and MDSAP certificates.

International Compliance

Case For Quality Belly-Flop? FDA's PMA Critical-To-Quality Pilot Has Zero Enrollees After 10 Months

Device-makers have given a collective shrug to US FDA's Premarket Approval Critical-to-Quality (PMA CtQ) pilot program, a Case for Quality initiative that aims to identify "critical-to-quality" attributes for an array of products and ensure that quality is built into devices at their earliest stages. Since the pilot began in September 2017, no firms have enrolled. FDA's Bleta Vuniqi surmises that the empty pilot might be a victim of a glut of FDA pilot programs. Meanwhile, the agency has been talking internally about ways that the fledgling PMA CtQ pilot could be absorbed by FDA's burgeoning CMMI maturity model pilot.

Quality FDA

Commercial Explore this Topic

Set Alert for Commercial

Boston Scientific Buys Venous Stent-Developer Veniti For $160M

Boston Scientific has agreed to pay up to $160m for the remaining 75% of Veniti Inc. that it does not already own. Veniti is a privately held Fremont, Calif. company that has developed and commercialized the Vici venous stent system for treating venous obstructive disease. The transaction price includes $108m upfront and $52m contingent on US FDA approval of Vici.

M & A Deals Clinical Trials

UK Medtechs' Brexit Readiness Moves Up A Notch In Absence Of EU Deal Framework

The UK is unmistakeably in the period of the calm before the storm, and an enforced Brexit lull is in place. But the thoughts of UK and EU decision-makers – and UK medtech companies – are not straying too far from the upcoming trade deal negotiations and the business of making the best of Brexit, however and whenever it manifests itself.

EU United Kingdom

Profusa Raised $45m To Market PAD-Monitoring Implant In Europe

Digital Health company Profusa raised more than $45m in a series C financing round. The company plans to use the proceeds to bring its tiny CE-marked injectable biosensors, used to monitor tissue oxygenation in patients with peripheral artery disease, to key opinion leaders and clinicians in Europe.

Wound Management Digital Health

Exoskeleton Company Ekso Bionics Names John (Jack) Glenn as CFO

Richmond, Calif.-based exoskeleton company Ekso Bionics named Jack Glenn as chief financial officer.

Appointments Commercial

Laboratory For Advanced Medicine (LAM) Appoints Chief Regulatory Officer

Liquid biopsy developer Laboratory for Advanced Medicine (LAM) named Jinjie Hu as chief regulatory officer.

Appointments Commercial

QUOTED. Aug. 8, 2018. Steve Williamson.

Global medtech player Becton Dickinson recently wrapped up an all-cash deal to acquire TVA Medical, which makes an endovascular arteriovenous (AV) fistula creation technology called the everlinQ endoAVF System. See what Steve Williamson, BD's president of Peripheral Intervention, said about it here.

Quoted M & A

ElectroCore Brings Next-Gen Vagus Nerve Stimulator To US With Innovative Sales Channel

US FDA cleared the gammaCore Sapphire non-invasive vagus nerve stimulator for the acute treatment of pain associated with migraine and episodic cluster headache. Electrocore also recently signed a deal with UpScript to provide a direct-to-patient sales channel for gammaCore.

Approvals Commercial

Clinical R&D Explore this Topic

Set Alert for Clinical R&D

Starts & Stops: July 29-Aug. 5, 2018

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made between July 29 and August 5, including trial announcements from ResApp Health, JenaValve, ReShape Lifesciences, Biotronik AG, and Pulse Biosciences.

Starts & Stops Clinical Trials Research & Development

Global Device Approvals, Weekly Snapshot: Aug. 6-12, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker. This week, a new microstent for glaucoma was approved by US FDA.

Approvals Ophthalmology

Starts & Stops: Aug. 6-12, 2018

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made Aug. 6 through 12, including trial announcements from Hancock Jaffe, Medtronic, and LivaNova.

Starts & Stops Clinical Trials

LivaNova Finishes Feasibility Trial Of Transcatheter Mitral Valve, Anticipates 2020 CE Mark

PRELUDE feasibility study of LivaNova's Caisson transseptal transcatheter mitral valve replacement (TMVR) system is complete and the company the INTERLUDE CE Mark trial has begun, the company announced. The company is now working with the US FDA to finalize the protocol for the ENSEMBLE US pivotal trial.

Clinical Trials Innovation

QUOTED. Aug. 10, 2018. Ted Davis.

Active Implants is ramping up for a 2019 commercial launch of its NUsurface polycarbonate-urethane meniscus implant as it continues clinical trials in the US. The firm hopes to earn US approval for the device by the end of 2020. See what Active Implants CEO Ted Davis said about it here.

Quoted Clinical Trials

Global Device Approvals, Weekly Snapshot: July 30-Aug. 5, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker. This week, EU and Australia approvals for Baxter's new infusion system, and more.

Approvals Research & Development

Active Implants Plans 2019 Commercial Release For NUsurface Meniscus Implant

Active Implants announced the completion of patient enrollment in the VENUS randomized trial of the NUsurface meniscus implant for the treatment of persistent knee pain caused by injured or deteriorated meniscus tissue. VENUS is designed to support a de novo clearance from US FDA, which would make it the first artificial meniscus approved in the US. NUsurface already has a CE mark and the company is planning to start a limited commercial release outside the US in 2019.

Clinical Trials Orthopedics
UsernamePublicRestriction

Register

Advertisement